1 of 5
The global apheresis market was valued at $2,560.4 million in 2016, and is expected to reach $4,200.6 million by 2023, registering a CAGR of 7.3% from 2017 to 2023. Apheresis procedures involve separation of desired components from the blood, while the remaining is either returned to the donor or the patient.
Use of large-scale plasma donations in the treatment of trauma patients, burn victims, and patients suffering from serious illness or injuries primarily contributes towards the growth of the apheresis market. In addition, rise in prevalence of cancer and surge in number of patients undergoing surgery have increased the number of plateletpheresis across the globe, thereby supplementing the market growth. However, dearth of skilled professionals and post-procedural complications associated with apheresis are anticipated to hamper the market growth. On the contrary, advancements in the healthcare sector in emerging economies are expected to offer significant profitable opportunities for the market players.
The global apheresis market is segmented based on product, method, procedure, component, end user, and region. On the basis of product, the market is classified into devices, disposable & reagents, and software. By method, it is categorized into centrifugation, membrane separation, and selective adsorption. Depending on procedure, it is divided into donor/automated apheresis and therapeutic apheresis. According to component, it is fragmented into plasma (plasmapheresis), platelets (plateletpheresis), leukocytes (leukapheresis), lymphocytes (lymph apheresis), and RBCS (erythropheresis). The end users covered in the study include blood centers, hospitals, and others. Regionally, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS
By Product
READ MORE Use of large-scale plasma donations in the treatment of trauma patients, burn victims, and patients suffering from serious illness or injuries primarily contributes towards the growth of the apheresis market. In addition, rise in prevalence of cancer and surge in number of patients undergoing surgery have increased the number of plateletpheresis across the globe, thereby supplementing the market growth. However, dearth of skilled professionals and post-procedural complications associated with apheresis are anticipated to hamper the market growth. On the contrary, advancements in the healthcare sector in emerging economies are expected to offer significant profitable opportunities for the market players.
The global apheresis market is segmented based on product, method, procedure, component, end user, and region. On the basis of product, the market is classified into devices, disposable & reagents, and software. By method, it is categorized into centrifugation, membrane separation, and selective adsorption. Depending on procedure, it is divided into donor/automated apheresis and therapeutic apheresis. According to component, it is fragmented into plasma (plasmapheresis), platelets (plateletpheresis), leukocytes (leukapheresis), lymphocytes (lymph apheresis), and RBCS (erythropheresis). The end users covered in the study include blood centers, hospitals, and others. Regionally, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS
- The study provides an in-depth analysis of the global apheresis market with the current trends and future estimations to elucidate the imminent investment pockets.
- Comprehensive analysis of the factors that drive and restrict the market growth is provided.
- Comprehensive quantitative analysis of the industry is provided from 2016 to 2023 to assist stakeholders to capitalize on the prevailing market opportunities.
- Extensive analysis of the key segments of the industry helps to understand the trends in apheresis globally.
- Key players and their strategies are provided to understand the competitive outlook of the industry.
By Product
- Devices
- Disposable & Reagents
- Software
- Centrifugation
- Intermittent Flow Centrifugation
- Continuous Flow Centrifugation
- Membrane Separation
- Selective Adsorption
- Donor/Automated Apheresis
- Therapeutic Apheresis
- Type
- Plasma Exchange
- Stem Cell Harvest
- Photopheresis
- Low Density Lipid Removal
- Other Procedures
- Application
- Hematology
- Neurology
- Oncology
- Others
- Plasma (Plasmapheresis)
- Platelets (Plateletpheresis)
- Leukocytes (Leukapheresis)
- Lymphocytes (Lymph Apheresis)
- RBCs (Erythropheresis)
- Blood Centers
- Hospitals
- Other End Users
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- France
- Germany
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- Rest of Asia-Pacific
- LAMEA
- Brazil
- South Africa
- Turkey
- Saudi Arabia
- Rest of LAMEA
- Haemonetics Corporation
- Fresenius Kabi
- Terumo BCT, Inc.
- Asahi Kasei Medical Co., Ltd.
- HemaCare Corporation
- Kaneka Corporation
- Kawasumi Laboratories Inc.
- Cerus Corporation
- B. Braun Melsungen AG
- Nikkiso Co., Ltd.
- Grifols International SA
- Baxter International Inc.
- CSL Behring
- Immucor
- Becton, Dickinson & Co.
- Abbott Laboratories
- Medicap
- Bioelettronica
Note: Product cover images may vary from those shown
2 of 5
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top winning strategies
3.2.2. Top investment pockets
3.3. Porters five forces analysis
3.4. Market share analysis
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Soaring demand for blood components across the globe
3.5.1.2. Increase in the government initiatives regarding blood donation
3.5.1.3. Newly approved indications for apheresis treatment
3.5.2. Restraints
3.5.2.1. Dearth of skilled professionals
3.5.2.2. Complications associated with the apheresis procedure
3.5.3. Opportunity
3.5.3.1. Rise in the demand for plasma-derived pharmaceuticals
CHAPTER 4: APHERESIS MARKET BY PRODUCT
4.1. Overview
4.1.1. Market size and forecast
4.2. Devices
4.2.1. Key trends and opportunities
4.2.2. Market size and forecast
4.2.3. Market analysis, by country
4.3. Disposables & Reagents
4.3.1. Key trends and opportunities
4.3.2. Market size and forecast
4.3.3. Market analysis, by country
4.4. Software
4.4.1. Key trends and opportunities
4.4.2. Market size and forecast
4.4.3. Market analysis, by country
CHAPTER 5: APHERESIS MARKET BY PROCEDURE
5.1. Overview
5.1.1. Market size and forecast
5.2. Donor/Automated Apheresis
5.2.1. Market size and forecast
5.2.2. Market analysis, by country
5.3. Therapeutic Apheresis
5.3.1. Market size and forecast
5.3.2. Market analysis, by country
5.3.3. Therapeutic Apheresis Market by Type
5.3.3.1. Market size and forecast
5.3.3.2. Plasma Exchange
5.3.3.2.1. Market size and forecast
5.3.3.3. Stem Cell Harvest
5.3.3.3.1. Market size and forecast
5.3.3.4. Photopheresis
5.3.3.4.1. Market size and forecast
5.3.3.5. Low Density Lipid Removal
5.3.3.5.1. Market size and forecast
5.3.3.6. Other Therapeutic Type
5.3.3.6.1. Market size and forecast
5.3.4. Therapeutic Apheresis Market by Specialty
5.3.4.1. Market size and forecast
5.3.4.2. Hematology
5.3.4.2.1. Market size and forecast
5.3.4.3. Neurology
5.3.4.3.1. Market size and forecast
5.3.4.4. Oncology
5.3.4.4.1. Market size and forecast
5.3.4.5. Other Therapeutic Application
5.3.4.5.1. Market size and forecast
CHAPTER 6: APHERESIS MARKET BY METHOD
6.1. Overview
6.1.1. Market size and forecast
6.2. Centrifugation
6.2.1. Market size and forecast
6.2.2. Market analysis, by country
6.2.3. Intermittent Flow Centrifugation
6.2.3.1. Market size and forecast
6.2.4. Continuous Flow Centrifugation
6.2.4.1. Market size and forecast
6.3. Membrane Separation
6.3.1. Market size and forecast
6.3.2. Market analysis, by country
6.4. Selective Adsorption
6.4.1. Market size and forecast
6.4.2. Market analysis, by country
CHAPTER 7: APHERESIS MARKET BY COMPONENT
7.1. Overview
7.1.1. Market size and forecast
7.2. Plasma (Plasmapheresis)
7.2.1. Market size and forecast
7.2.2. Market analysis, by country
7.3. Platelets (Plateletpheresis)
7.3.1. Market size and forecast
7.3.2. Market analysis, by country
7.4. Leukocytes (Leukapheresis)
7.4.1. Market size and forecast
7.4.2. Market analysis, by country
7.5. Lymphocytes (Lymph apheresis)
7.5.1. Market size and forecast
7.5.2. Market analysis, by country
7.6. RBC's (Erythropheresis)
7.6.1. Market size and forecast
7.6.2. Market analysis, by country
CHAPTER 8: APHERESIS MARKET BY END USER
8.1. Overview
8.1.1. Market size and forecast
8.2. Blood Centers
8.2.1. Market size and forecast
8.2.2. Market analysis, by country
8.3. Hospitals
8.3.1. Market size and forecast
8.3.2. Market analysis, by country
8.4. Other end users
8.4.1. Market size and forecast
8.4.2. Market analysis, by country
CHAPTER 9: APHERESIS MARKET BY REGION
9.1. Overview
9.1.1. Market size and forecast
9.2. North America
9.2.1. Key trends and opportunities
9.2.2. North America market size & forecast by country
9.2.3. North America market size & forecast by product
9.2.4. North America market size & forecast by method
9.2.5. North America market size & forecast by procedure
9.2.6. North America market size & forecast by component
9.2.7. North America market size & forecast by end user
9.2.7.1. U.S. market size & forecast by product
9.2.7.2. U.S. market size & forecast by method
9.2.7.3. U.S. market size & forecast by procedure
9.2.7.4. U.S. market size & forecast by component
9.2.7.5. U.S. market size & forecast by end user
9.2.7.6. Canada market size & forecast by product
9.2.7.7. Canada market size & forecast by method
9.2.7.8. Canada market size & forecast by procedure
9.2.7.9. Canada market size & forecast by component
9.2.7.10. Canada market size & forecast by end user
9.2.7.11. Mexico market size & forecast by product
9.2.7.12. Mexico market size & forecast by method
9.2.7.13. Mexico market size & forecast by procedure
9.2.7.14. Mexico market size & forecast by component
9.2.7.15. Mexico market size & forecast by end user
9.3. Europe
9.3.1. Key trends and opportunities
9.3.2. Europe market size & forecast for apheresis market by country
9.3.3. Europe market size & forecast by product
9.3.4. Europe market size & forecast by method
9.3.5. Europe market size & forecast by procedure
9.3.6. Europe market size & forecast by component
9.3.7. Europe market size & forecast by end user
9.3.7.1. Germany market size & forecast by product
9.3.7.2. Germany market size & forecast by method
9.3.7.3. Germany market size & forecast by procedure
9.3.7.4. Germany market size & forecast by component
9.3.7.5. Germany market size & forecast by end user
9.3.7.6. France market size & forecast by product
9.3.7.7. France market size & forecast by method
9.3.7.8. France market size & forecast by procedure
9.3.7.9. France market size & forecast by component
9.3.7.10. France market size & forecast by end user
9.3.7.11. UK market size & forecast by product
9.3.7.12. UK market size & forecast by method
9.3.7.13. UK market size & forecast by procedure
9.3.7.14. UK market size & forecast by component
9.3.7.15. UK market size & forecast by end user
9.3.7.16. Italy market size & forecast by product
9.3.7.17. Italy market size & forecast by method
9.3.7.18. Italy market size & forecast by procedure
9.3.7.19. Italy market size & forecast by component
9.3.7.20. Italy market size & forecast by end user
9.3.7.21. Spain market size & forecast by product
9.3.7.22. Spain market size & forecast by method
9.3.7.23. Spain market size & forecast by procedure
9.3.7.24. Spain market size & forecast by component
9.3.7.25. Spain market size & forecast by end user
9.3.7.26. Rest of Europe market size & forecast by product
9.3.7.27. Rest of Europe market size & forecast by method
9.3.7.28. Rest of Europe market size & forecast by procedure
9.3.7.29. Rest of Europe market size & forecast by component
9.3.7.30. Rest of Europe market size & forecast by end user
9.4. Asia-Pacific
9.4.1. Key trends and opportunities
9.4.2. Asia-Pacific market size & forecast by country
9.4.3. Asia-Pacific market size & forecast by product
9.4.4. Asia-Pacific market size & forecast by method
9.4.5. Asia-Pacific market size & forecast by procedure
9.4.6. Asia-Pacific market size & forecast by component
9.4.7. Asia-Pacific market size & forecast by end user
9.4.7.1. Japan market size & forecast by product
9.4.7.2. Japan market size & forecast by method
9.4.7.3. Japan market size & forecast by procedure
9.4.7.4. Japan market size & forecast by component
9.4.7.5. Japan market size & forecast by end user
9.4.7.6. China market size & forecast by product
9.4.7.7. China market size & forecast by method
9.4.7.8. China market size & forecast by procedure
9.4.7.9. China market size & forecast by component
9.4.7.10. China market size & forecast by end user
9.4.7.11. India market size & forecast by product
9.4.7.12. India market size & forecast by method
9.4.7.13. India market size & forecast by procedure
9.4.7.14. India market size & forecast by component
9.4.7.15. India market size & forecast by end user
9.4.7.16. Australia market size & forecast by product
9.4.7.17. Australia market size & forecast by method
9.4.7.18. Australia market size & forecast by procedure
9.4.7.19. Australia market size & forecast by component
9.4.7.20. Australia market size & forecast by end user
9.4.7.21. Rest of Asia-Pacific market size & forecast by product
9.4.7.22. Rest of Asia-Pacific market size & forecast by method
9.4.7.23. Rest of Asia-Pacific market size & forecast by procedure
9.4.7.24. Rest of Asia-Pacific market size & forecast by component
9.4.7.25. Rest of Asia-Pacific market size & forecast by end user
9.5. LAMEA
9.5.1. Key trends and opportunities
9.5.2. LAMEA market size & forecast by country
9.5.3. LAMEA market size & forecast by product
9.5.4. LAMEA market size & forecast by method
9.5.5. LAMEA market size & forecast by procedure
9.5.6. LAMEA market size & forecast by component
9.5.7. LAMEA market size & forecast by end user
9.5.7.1. Brazil market size & forecast by product
9.5.7.2. Brazil market size & forecast by method
9.5.7.3. Brazil market size & forecast by procedure
9.5.7.4. Brazil market size & forecast by component
9.5.7.5. Brazil market size & forecast by end user
9.5.7.6. South Africa market size & forecast by product
9.5.7.7. South Africa market size & forecast by method
9.5.7.8. South Africa market size & forecast by procedure
9.5.7.9. South Africa market size & forecast by component
9.5.7.10. South Africa market size & forecast by end user
9.5.7.11. Turkey market size & forecast by product
9.5.7.12. Turkey market size & forecast by method
9.5.7.13. Turkey market size & forecast by procedure
9.5.7.14. Turkey market size & forecast by component
9.5.7.15. Turkey market size & forecast by end user
9.5.7.16. Saudi Arabia market size & forecast by product
9.5.7.17. Saudi Arabia market size & forecast by method
9.5.7.18. Saudi Arabia market size & forecast by procedure
9.5.7.19. Saudi Arabia market size & forecast by component
9.5.7.20. Saudi Arabia market size & forecast by end user
9.5.7.21. Rest of LAMEA market size & forecast by product
9.5.7.22. Rest of LAMEA market size & forecast by method
9.5.7.23. Rest of LAMEA market size & forecast by procedure
9.5.7.24. Rest of LAMEA market size & forecast by component
9.5.7.25. Rest of LAMEA market size & forecast by end user
CHAPTER 10: COMPANY PROFILE
10.1. Haemonetics Corporation
10.1.1. Company overview
10.1.2. Company snapshot
10.1.3. Operating business segments
10.1.4. Business performance
10.1.5. Key strategic moves and developments
10.2. Fresenius Kabi
10.2.1. Company overview
10.2.2. Company snapshot
10.2.3. Operating business segments
10.2.4. Business performance
10.2.5. Key strategic moves and developments
10.3. Terumo BCT, Inc.
10.3.1. Company overview
10.3.2. Company snapshot
10.3.3. Operating business segments
10.3.4. Business performance
10.3.5. Key strategic moves and developments
10.4. Asahi Kasei Medical Co., Ltd.
10.4.1. Company overview
10.4.2. Company snapshot
10.4.3. Operating business segments
10.4.4. Business performance
10.4.5. Key strategic moves and developments
10.5. HemaCare Corporation
10.5.1. Company overview
10.5.2. Company snapshot
10.5.3. Operating business segments
10.5.4. Business performance
10.5.5. Key strategic moves and developments
10.6. Kaneka Corporation
10.6.1. Company overview
10.6.2. Company snapshot
10.6.3. Operating business segments
10.6.4. Business performance
10.6.5. Key strategic moves and developments
10.7. Kawasumi Laboratories Inc.
10.7.1. Company overview
10.7.2. Company snapshot
10.7.3. Operating business segments
10.7.4. Business performance
10.7.5. Key strategic moves and developments
10.8. Cerus Corporation
10.8.1. Company overview
10.8.2. Company snapshot
10.8.3. Operating business segments
10.8.4. Business performance
10.8.5. Key strategic moves and developments
10.9. B. Braun Melsungen AG
10.9.1. Company overview
10.9.2. Company snapshot
10.9.3. Operating business segments
10.9.4. Business performance
10.9.5. Key strategic moves and developments
10.10. Nikkiso Co., Ltd.
10.10.1. Company overview
10.10.2. Company snapshot
10.10.3. Operating business segments
10.10.4. Business performance
10.10.5. Key strategic moves and developments
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top winning strategies
3.2.2. Top investment pockets
3.3. Porters five forces analysis
3.4. Market share analysis
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Soaring demand for blood components across the globe
3.5.1.2. Increase in the government initiatives regarding blood donation
3.5.1.3. Newly approved indications for apheresis treatment
3.5.2. Restraints
3.5.2.1. Dearth of skilled professionals
3.5.2.2. Complications associated with the apheresis procedure
3.5.3. Opportunity
3.5.3.1. Rise in the demand for plasma-derived pharmaceuticals
CHAPTER 4: APHERESIS MARKET BY PRODUCT
4.1. Overview
4.1.1. Market size and forecast
4.2. Devices
4.2.1. Key trends and opportunities
4.2.2. Market size and forecast
4.2.3. Market analysis, by country
4.3. Disposables & Reagents
4.3.1. Key trends and opportunities
4.3.2. Market size and forecast
4.3.3. Market analysis, by country
4.4. Software
4.4.1. Key trends and opportunities
4.4.2. Market size and forecast
4.4.3. Market analysis, by country
CHAPTER 5: APHERESIS MARKET BY PROCEDURE
5.1. Overview
5.1.1. Market size and forecast
5.2. Donor/Automated Apheresis
5.2.1. Market size and forecast
5.2.2. Market analysis, by country
5.3. Therapeutic Apheresis
5.3.1. Market size and forecast
5.3.2. Market analysis, by country
5.3.3. Therapeutic Apheresis Market by Type
5.3.3.1. Market size and forecast
5.3.3.2. Plasma Exchange
5.3.3.2.1. Market size and forecast
5.3.3.3. Stem Cell Harvest
5.3.3.3.1. Market size and forecast
5.3.3.4. Photopheresis
5.3.3.4.1. Market size and forecast
5.3.3.5. Low Density Lipid Removal
5.3.3.5.1. Market size and forecast
5.3.3.6. Other Therapeutic Type
5.3.3.6.1. Market size and forecast
5.3.4. Therapeutic Apheresis Market by Specialty
5.3.4.1. Market size and forecast
5.3.4.2. Hematology
5.3.4.2.1. Market size and forecast
5.3.4.3. Neurology
5.3.4.3.1. Market size and forecast
5.3.4.4. Oncology
5.3.4.4.1. Market size and forecast
5.3.4.5. Other Therapeutic Application
5.3.4.5.1. Market size and forecast
CHAPTER 6: APHERESIS MARKET BY METHOD
6.1. Overview
6.1.1. Market size and forecast
6.2. Centrifugation
6.2.1. Market size and forecast
6.2.2. Market analysis, by country
6.2.3. Intermittent Flow Centrifugation
6.2.3.1. Market size and forecast
6.2.4. Continuous Flow Centrifugation
6.2.4.1. Market size and forecast
6.3. Membrane Separation
6.3.1. Market size and forecast
6.3.2. Market analysis, by country
6.4. Selective Adsorption
6.4.1. Market size and forecast
6.4.2. Market analysis, by country
CHAPTER 7: APHERESIS MARKET BY COMPONENT
7.1. Overview
7.1.1. Market size and forecast
7.2. Plasma (Plasmapheresis)
7.2.1. Market size and forecast
7.2.2. Market analysis, by country
7.3. Platelets (Plateletpheresis)
7.3.1. Market size and forecast
7.3.2. Market analysis, by country
7.4. Leukocytes (Leukapheresis)
7.4.1. Market size and forecast
7.4.2. Market analysis, by country
7.5. Lymphocytes (Lymph apheresis)
7.5.1. Market size and forecast
7.5.2. Market analysis, by country
7.6. RBC's (Erythropheresis)
7.6.1. Market size and forecast
7.6.2. Market analysis, by country
CHAPTER 8: APHERESIS MARKET BY END USER
8.1. Overview
8.1.1. Market size and forecast
8.2. Blood Centers
8.2.1. Market size and forecast
8.2.2. Market analysis, by country
8.3. Hospitals
8.3.1. Market size and forecast
8.3.2. Market analysis, by country
8.4. Other end users
8.4.1. Market size and forecast
8.4.2. Market analysis, by country
CHAPTER 9: APHERESIS MARKET BY REGION
9.1. Overview
9.1.1. Market size and forecast
9.2. North America
9.2.1. Key trends and opportunities
9.2.2. North America market size & forecast by country
9.2.3. North America market size & forecast by product
9.2.4. North America market size & forecast by method
9.2.5. North America market size & forecast by procedure
9.2.6. North America market size & forecast by component
9.2.7. North America market size & forecast by end user
9.2.7.1. U.S. market size & forecast by product
9.2.7.2. U.S. market size & forecast by method
9.2.7.3. U.S. market size & forecast by procedure
9.2.7.4. U.S. market size & forecast by component
9.2.7.5. U.S. market size & forecast by end user
9.2.7.6. Canada market size & forecast by product
9.2.7.7. Canada market size & forecast by method
9.2.7.8. Canada market size & forecast by procedure
9.2.7.9. Canada market size & forecast by component
9.2.7.10. Canada market size & forecast by end user
9.2.7.11. Mexico market size & forecast by product
9.2.7.12. Mexico market size & forecast by method
9.2.7.13. Mexico market size & forecast by procedure
9.2.7.14. Mexico market size & forecast by component
9.2.7.15. Mexico market size & forecast by end user
9.3. Europe
9.3.1. Key trends and opportunities
9.3.2. Europe market size & forecast for apheresis market by country
9.3.3. Europe market size & forecast by product
9.3.4. Europe market size & forecast by method
9.3.5. Europe market size & forecast by procedure
9.3.6. Europe market size & forecast by component
9.3.7. Europe market size & forecast by end user
9.3.7.1. Germany market size & forecast by product
9.3.7.2. Germany market size & forecast by method
9.3.7.3. Germany market size & forecast by procedure
9.3.7.4. Germany market size & forecast by component
9.3.7.5. Germany market size & forecast by end user
9.3.7.6. France market size & forecast by product
9.3.7.7. France market size & forecast by method
9.3.7.8. France market size & forecast by procedure
9.3.7.9. France market size & forecast by component
9.3.7.10. France market size & forecast by end user
9.3.7.11. UK market size & forecast by product
9.3.7.12. UK market size & forecast by method
9.3.7.13. UK market size & forecast by procedure
9.3.7.14. UK market size & forecast by component
9.3.7.15. UK market size & forecast by end user
9.3.7.16. Italy market size & forecast by product
9.3.7.17. Italy market size & forecast by method
9.3.7.18. Italy market size & forecast by procedure
9.3.7.19. Italy market size & forecast by component
9.3.7.20. Italy market size & forecast by end user
9.3.7.21. Spain market size & forecast by product
9.3.7.22. Spain market size & forecast by method
9.3.7.23. Spain market size & forecast by procedure
9.3.7.24. Spain market size & forecast by component
9.3.7.25. Spain market size & forecast by end user
9.3.7.26. Rest of Europe market size & forecast by product
9.3.7.27. Rest of Europe market size & forecast by method
9.3.7.28. Rest of Europe market size & forecast by procedure
9.3.7.29. Rest of Europe market size & forecast by component
9.3.7.30. Rest of Europe market size & forecast by end user
9.4. Asia-Pacific
9.4.1. Key trends and opportunities
9.4.2. Asia-Pacific market size & forecast by country
9.4.3. Asia-Pacific market size & forecast by product
9.4.4. Asia-Pacific market size & forecast by method
9.4.5. Asia-Pacific market size & forecast by procedure
9.4.6. Asia-Pacific market size & forecast by component
9.4.7. Asia-Pacific market size & forecast by end user
9.4.7.1. Japan market size & forecast by product
9.4.7.2. Japan market size & forecast by method
9.4.7.3. Japan market size & forecast by procedure
9.4.7.4. Japan market size & forecast by component
9.4.7.5. Japan market size & forecast by end user
9.4.7.6. China market size & forecast by product
9.4.7.7. China market size & forecast by method
9.4.7.8. China market size & forecast by procedure
9.4.7.9. China market size & forecast by component
9.4.7.10. China market size & forecast by end user
9.4.7.11. India market size & forecast by product
9.4.7.12. India market size & forecast by method
9.4.7.13. India market size & forecast by procedure
9.4.7.14. India market size & forecast by component
9.4.7.15. India market size & forecast by end user
9.4.7.16. Australia market size & forecast by product
9.4.7.17. Australia market size & forecast by method
9.4.7.18. Australia market size & forecast by procedure
9.4.7.19. Australia market size & forecast by component
9.4.7.20. Australia market size & forecast by end user
9.4.7.21. Rest of Asia-Pacific market size & forecast by product
9.4.7.22. Rest of Asia-Pacific market size & forecast by method
9.4.7.23. Rest of Asia-Pacific market size & forecast by procedure
9.4.7.24. Rest of Asia-Pacific market size & forecast by component
9.4.7.25. Rest of Asia-Pacific market size & forecast by end user
9.5. LAMEA
9.5.1. Key trends and opportunities
9.5.2. LAMEA market size & forecast by country
9.5.3. LAMEA market size & forecast by product
9.5.4. LAMEA market size & forecast by method
9.5.5. LAMEA market size & forecast by procedure
9.5.6. LAMEA market size & forecast by component
9.5.7. LAMEA market size & forecast by end user
9.5.7.1. Brazil market size & forecast by product
9.5.7.2. Brazil market size & forecast by method
9.5.7.3. Brazil market size & forecast by procedure
9.5.7.4. Brazil market size & forecast by component
9.5.7.5. Brazil market size & forecast by end user
9.5.7.6. South Africa market size & forecast by product
9.5.7.7. South Africa market size & forecast by method
9.5.7.8. South Africa market size & forecast by procedure
9.5.7.9. South Africa market size & forecast by component
9.5.7.10. South Africa market size & forecast by end user
9.5.7.11. Turkey market size & forecast by product
9.5.7.12. Turkey market size & forecast by method
9.5.7.13. Turkey market size & forecast by procedure
9.5.7.14. Turkey market size & forecast by component
9.5.7.15. Turkey market size & forecast by end user
9.5.7.16. Saudi Arabia market size & forecast by product
9.5.7.17. Saudi Arabia market size & forecast by method
9.5.7.18. Saudi Arabia market size & forecast by procedure
9.5.7.19. Saudi Arabia market size & forecast by component
9.5.7.20. Saudi Arabia market size & forecast by end user
9.5.7.21. Rest of LAMEA market size & forecast by product
9.5.7.22. Rest of LAMEA market size & forecast by method
9.5.7.23. Rest of LAMEA market size & forecast by procedure
9.5.7.24. Rest of LAMEA market size & forecast by component
9.5.7.25. Rest of LAMEA market size & forecast by end user
CHAPTER 10: COMPANY PROFILE
10.1. Haemonetics Corporation
10.1.1. Company overview
10.1.2. Company snapshot
10.1.3. Operating business segments
10.1.4. Business performance
10.1.5. Key strategic moves and developments
10.2. Fresenius Kabi
10.2.1. Company overview
10.2.2. Company snapshot
10.2.3. Operating business segments
10.2.4. Business performance
10.2.5. Key strategic moves and developments
10.3. Terumo BCT, Inc.
10.3.1. Company overview
10.3.2. Company snapshot
10.3.3. Operating business segments
10.3.4. Business performance
10.3.5. Key strategic moves and developments
10.4. Asahi Kasei Medical Co., Ltd.
10.4.1. Company overview
10.4.2. Company snapshot
10.4.3. Operating business segments
10.4.4. Business performance
10.4.5. Key strategic moves and developments
10.5. HemaCare Corporation
10.5.1. Company overview
10.5.2. Company snapshot
10.5.3. Operating business segments
10.5.4. Business performance
10.5.5. Key strategic moves and developments
10.6. Kaneka Corporation
10.6.1. Company overview
10.6.2. Company snapshot
10.6.3. Operating business segments
10.6.4. Business performance
10.6.5. Key strategic moves and developments
10.7. Kawasumi Laboratories Inc.
10.7.1. Company overview
10.7.2. Company snapshot
10.7.3. Operating business segments
10.7.4. Business performance
10.7.5. Key strategic moves and developments
10.8. Cerus Corporation
10.8.1. Company overview
10.8.2. Company snapshot
10.8.3. Operating business segments
10.8.4. Business performance
10.8.5. Key strategic moves and developments
10.9. B. Braun Melsungen AG
10.9.1. Company overview
10.9.2. Company snapshot
10.9.3. Operating business segments
10.9.4. Business performance
10.9.5. Key strategic moves and developments
10.10. Nikkiso Co., Ltd.
10.10.1. Company overview
10.10.2. Company snapshot
10.10.3. Operating business segments
10.10.4. Business performance
10.10.5. Key strategic moves and developments
Note: Product cover images may vary from those shown
3 of 5
LOADING...
4 of 5
According to a new report titled, Apheresis Market by Product, Method, Procedure, Component, and End User: Global Opportunity Analysis and Industry Forecast, 2017-2023, the global apheresis market was valued at $2,560.4 million in 2016, and is projected to reach $4,200.6 million by 2023, growing at a CAGR of 7.3% from 2017 to 2023. The disposable & reagents segment accounted for four-ninths of the total market share in 2016.
Apheresis system assists in the collection and separation of blood components for donation. In addition, this system can perform removal or exchange of blood components for therapeutic procedures. The American National Red Cross offers various therapeutic apheresis services across the U.S. that include plasmapheresis, photopheresis, LDL apheresis, and stem cell harvest. In addition, the center has employed qualified and specialized staff for apheresis procedures while maintaining the accessibility and availability regarding the same. Increase in the number of such blood centers across the globe significantly drives the growth of the apheresis market.
In addition, rise in government initiatives that promote blood donations in the developing countries such as China and India propels the market growth. For instance, Twitter has recently launched a social initiative called BloodMatters in India on March 2018. Twitter has collaborated with the voluntary blood donation helpline named Blood Donors. Moreover, increase in number of blood donations was observed in China in 2014, which led to increase in the number of blood centers in the country. Such circumstances positively impact the market growth.
The centrifugation method generated the highest revenue in 2016, and is expected to maintain this dominance throughout the forecast period. This is attributed to the fact that centrifugation is considered to be a standard method for apheresis, and is highly favored by the blood industry across the globe. However, the membrane separation segment is expected to register the highest growth rate during the forecast period, owing to rise in demand for membrane separation apheresis, as it prevents the need for replacement fluids by not depleting the blood coagulation factors.
Based on procedure, the market is divided into donor/automated apheresis and therapeutic apheresis. Donor/automated apheresis is anticipated to dominate the global market throughout the forecast period, due to increase in gap between blood supply and blood products, which facilitate the need for using apheresis machines. Moreover, rise in apheresis procedures across several specialties such as hematology, neurology, and oncology has contributed towards the robust growth displayed by this segment. The therapeutic apheresis is expected to grow at the highest rate from 2017 to 2023.
Key findings of the Apheresis Market:
The platelets (plateletpheresis) segment is expected to register the highest growth rate from 2017 to 2023.
Blood centers accounted for maximum revenue in 2016, and is anticipated to maintain this trend throughout the forecast period.
North America dominated the global apheresis market, accounting for maximum share in 2016, and is expected to retain the same trend during the forecast period.
Intermittent flow centrifugation segment dominated the centrifugation apheresis market in 2016 and is expected to maintain this trend during the forecast period.
Photopheresis is estimated to exhibit the highest CAGR of 9.3% from 2017 to 2023 in the therapeutic apheresis market.
Asia-Pacific is expected to witness the highest growth rate throughout the forecast period, due to its high population base, upsurge in disposable income, and rise in patient awareness towards blood donation. In addition, increase in incidence of dengue across countries in the Asia-Pacific region is the key contributor for the market growth in the region.
The major companies profiled in this report include Haemonetics Corporation, Fresenius Kabi, Terumo BCT, Inc., Asahi Kasei Medical Co., Ltd., HemaCare Corporation, Kaneka Corporation, Kawasumi Laboratories Inc., Cerus Corporation, B. Braun Melsungen AG, and Nikkiso Co., Ltd. Other prominent players in the value chain include Grifols International SA, Baxter International Inc., CSL Behring, Immucor, Becton, Dickinson & Co., Abbott Laboratories, Medicap, and Bioelettronica.
Apheresis system assists in the collection and separation of blood components for donation. In addition, this system can perform removal or exchange of blood components for therapeutic procedures. The American National Red Cross offers various therapeutic apheresis services across the U.S. that include plasmapheresis, photopheresis, LDL apheresis, and stem cell harvest. In addition, the center has employed qualified and specialized staff for apheresis procedures while maintaining the accessibility and availability regarding the same. Increase in the number of such blood centers across the globe significantly drives the growth of the apheresis market.
In addition, rise in government initiatives that promote blood donations in the developing countries such as China and India propels the market growth. For instance, Twitter has recently launched a social initiative called BloodMatters in India on March 2018. Twitter has collaborated with the voluntary blood donation helpline named Blood Donors. Moreover, increase in number of blood donations was observed in China in 2014, which led to increase in the number of blood centers in the country. Such circumstances positively impact the market growth.
The centrifugation method generated the highest revenue in 2016, and is expected to maintain this dominance throughout the forecast period. This is attributed to the fact that centrifugation is considered to be a standard method for apheresis, and is highly favored by the blood industry across the globe. However, the membrane separation segment is expected to register the highest growth rate during the forecast period, owing to rise in demand for membrane separation apheresis, as it prevents the need for replacement fluids by not depleting the blood coagulation factors.
Based on procedure, the market is divided into donor/automated apheresis and therapeutic apheresis. Donor/automated apheresis is anticipated to dominate the global market throughout the forecast period, due to increase in gap between blood supply and blood products, which facilitate the need for using apheresis machines. Moreover, rise in apheresis procedures across several specialties such as hematology, neurology, and oncology has contributed towards the robust growth displayed by this segment. The therapeutic apheresis is expected to grow at the highest rate from 2017 to 2023.
Key findings of the Apheresis Market:
The platelets (plateletpheresis) segment is expected to register the highest growth rate from 2017 to 2023.
Blood centers accounted for maximum revenue in 2016, and is anticipated to maintain this trend throughout the forecast period.
North America dominated the global apheresis market, accounting for maximum share in 2016, and is expected to retain the same trend during the forecast period.
Intermittent flow centrifugation segment dominated the centrifugation apheresis market in 2016 and is expected to maintain this trend during the forecast period.
Photopheresis is estimated to exhibit the highest CAGR of 9.3% from 2017 to 2023 in the therapeutic apheresis market.
Asia-Pacific is expected to witness the highest growth rate throughout the forecast period, due to its high population base, upsurge in disposable income, and rise in patient awareness towards blood donation. In addition, increase in incidence of dengue across countries in the Asia-Pacific region is the key contributor for the market growth in the region.
The major companies profiled in this report include Haemonetics Corporation, Fresenius Kabi, Terumo BCT, Inc., Asahi Kasei Medical Co., Ltd., HemaCare Corporation, Kaneka Corporation, Kawasumi Laboratories Inc., Cerus Corporation, B. Braun Melsungen AG, and Nikkiso Co., Ltd. Other prominent players in the value chain include Grifols International SA, Baxter International Inc., CSL Behring, Immucor, Becton, Dickinson & Co., Abbott Laboratories, Medicap, and Bioelettronica.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
